Thrive Pet Healthcare veterinarians address overfeeding, senior health and questions about GLP-1 treatments for pets AUSTIN, Texas, Jan. 28, 2026 /PRNewswire/ — As families refocus

The 23-time Grand Slam champion tells PEOPLE that she feels better than ever since dropping 34 lbs. with a GLP-1

With lower cholesterol and blood sugar levels, she’s says she’s healthier than ever.

GLP-1 receptor agonists, of which semaglutide (a.k.a. Ozempic) is the most well known example, has revolutionized obesity management. Though cost was a limiting factor for

By Harshita Mary Varghese and Patrick WingroveJan 28 (Reuters) – Novo Nordisk spent nearly $500 million ‌on ​U.S. advertising for its GLP-1 drugs…

Last year, for the first time, food consumption went down, reported the Financial Times, making 2025 “the first year on record where the volume of food consumed

GLP-1 drugs like Ozempic and Wegovy are everywhere — but thousands of users now allege the medications caused severe, life-altering injuries including everything from stomach

A new randomized trial shows that GLP-1 weight-loss drugs like liraglutide help reduce weight but don’t improve physical fitness on their own. Structured exercise is

Imagine hopping in a time machine, going back a century, and telling someone that today, if you have the money for it, you can walk

Hanmi Signs Exclusive Partnership with New Mexican Partner Laboratorios Sanfer, Covering Efpeglenatide and Diabetes Treatments SEOUL, South Korea, Jan. 27, 2026 /PRNewswire/ — Hanmi is

GLP-1 medications (like semaglutide and tirzepatide) have exploded in demand, but finding legitimate, accessible telehealth providers is still surprisingly hard — especially outside the US.

By ALI SWENSON NEW YORK (AP) — Drugs that treat Type 2 diabetes, HIV and arthritis are among 15 new medications chosen for a Medicare

Liraglutide, a GLP-1 receptor agonist, is used to induce weight loss. However, limited information exists on liraglutides effects on the gut bacterial community and their

Another GLP-1 drug is up for Medicare negotiations under the Inflation Reduction Act. Eli Lilly’s diabetes drug Trulicity is among 15 drugs selected for the

Preliminary Phase 2 data show Roche’s CT-388 led to a 22.5% placebo-adjusted weight loss measured at 48 weeks. Based on these results, the pharmaceutical company

Explore the shift from weight loss-focused drugs to overall health and anti-aging uses.

Millennials and GLP-1 users are fueling these trends and are willing to switch restaurant brands for more options

(MedPage Today) — Tirzepatide (Mounjaro, Zepbound) users should never share KwikPens due to risk for transmission of blood-borne pathogens, the FDA warned in an updated

The term “superfood” is sticky. It seems as though every few months, a new food lands in this lofty category of nourishments. Bamboo, a popular

A recent study highlights a surprising potential benefit of diabetes and obesity drugs, GLP-1 receptor agonists, in improving overall health and possibly extending survival in

A larger percentage of GLP-1 users say social media and online research are their most trusted source for microdosing information over their clinician. Medscape Medical

Abstract Aim Heart failure with preserved ejection fraction (HFpEF) presents a therapeutic challenge, characterised by a paucity of validated treatments. Emerging data suggest that targeting

CHILD star Amanda Bynes looks slimmer than ever in a new video after revealing she has been using weight loss jabs. At the end of

In today’s CEO Daily: Fortune Editor-in-Chief Alyson Shontell interviews Pfizer CEO Albert Bourla. The big story: Target’s incoming CEO speaks out about the immigration crackdown

As doctors learn why GLP-1s don’t work for about 50% of people, they are also learning more about the complex drivers of obesity. They foresee

Roche’s dual GLP-1/GIP receptor agonist has been tied to 22.5% weight loss at 48 weeks, validating the company’s decision to move the asset into phase

As GLP-1 adoption accelerates across the Middle East, Havas brings a unique specialized strategic cultural lens to the rapidly evolving metabolic economy

SAN FRANCISCO–(BUSINESS WIRE)– #SUD–Baseline Therapeutics, Inc. (“Baseline”), a clinical-stage biotechnology company developing addiction therapeutics, today announced the launch of the company to advance a new

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. A new

Key Points The pharmaceutical industry has a well-structured cycle. Eli Lilly is currently benefiting from the early stages of the cycle. In 10 years, if

Emerging evidence suggests that GLP-1 receptor agonists may improve muscle quality as body weight and lean mass decline. Medscape Gastroenterology

A drug Roche acquired in a multibillion-dollar deal could be as effective as Zepbound, but may struggle to stand out in a crowded field, analysts

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from CT388-103, a Phase

Gene therapy for weight loss is being explored as a potential game-changer, with therapy aiming to program the body to produce its own GLP-1 hormone

This randomized controlled trial shows that structured moderate-to-vigorous exercise, alone or combined with liraglutide, improves physical function and cardiorespiratory fitness after diet-induced weight loss in